No connection

Search Results

ABBV vs ADPT

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
ADPT
Adaptive Biotechnologies Corporation
BEARISH
Price
$13.17
Market Cap
$2.03B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ABBV
163.63
ADPT
--
Forward P/E
ABBV
15.42
ADPT
-48.78
P/B Ratio
ABBV
-146.66
ADPT
9.26
P/S Ratio
ABBV
6.5
ADPT
7.32
EV/EBITDA
ABBV
15.27
ADPT
-51.35

Profitability

Gross Margin
ABBV
71.46%
ADPT
74.24%
Operating Margin
ABBV
35.5%
ADPT
-17.82%
Profit Margin
ABBV
4.0%
ADPT
-21.48%
ROE
ABBV
137.96%
ADPT
-27.82%
ROA
ABBV
9.59%
ADPT
-6.79%

Growth

Revenue Growth
ABBV
9.1%
ADPT
51.0%
Earnings Growth
ABBV
-88.7%
ADPT
--

Financial Health

Debt/Equity
ABBV
--
ADPT
0.93
Current Ratio
ABBV
0.72
ADPT
3.34
Quick Ratio
ABBV
0.47
ADPT
3.1

Dividends

Dividend Yield
ABBV
3.05%
ADPT
--
Payout Ratio
ABBV
490.15%
ADPT
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
ADPT BEARISH

ADPT's Advanced Deterministic Scorecard reveals severe financial health concerns: a Piotroski F-Score of 1/9 indicates extreme weakness, with no positive signals in profitability, cash flow, or leverage management. The Altman Z-Score is unavailable, but the company's negative ROE (-27.82%), negative operating margin (-17.82%), and high debt/equity (0.93) suggest significant distress risk. Despite strong revenue growth (51% YoY) and a history of earnings surprises, the stock trades at a forward P/E of -48.78, reflecting deep losses and speculative valuation. Insider selling totaling $12.73M in six months further undermines confidence, signaling potential internal skepticism about near-term prospects.

Strengths
51.00% YoY revenue growth indicates strong top-line momentum
Gross margin of 74.24% reflects high product profitability and pricing power
Recent quarters have consistently beaten earnings estimates (3/4 in last 4)
Risks
Piotroski F-Score of 1/9 signals severe financial distress and poor operational health
Negative ROE (-27.82%) and ROA (-6.79%) indicate capital is not being effectively deployed
Insider selling of $12.73M in 6 months with no buys suggests internal confidence erosion

Compare Another Pair

ABBV vs ADPT: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Adaptive Biotechnologies Corporation (ADPT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile